Rocket Pharmaceuticals, Inc. news

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial
100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate
All patients showed clinical reversal of disease course, including statistically significant reduction in all-cause hospitalizations and incidence of severe infections
Initiating discussions with health authorities on filing plans; reg

May. 19, 2022